Vericel Corporation (VCEL)

Price$36.30

Value ScoreD

Growth ScoreB

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-17.74%

Price vs S&P 500 (4W)8.50%

VGM Score54.93

Market Capitalization$1.77B

P/E Ratio (Annual)107.40x

All Metrics

P/CF (Annual)34.18x

Book Value / Share (Quarterly)$6.98

P/TBV (Annual)5.22x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)18.89%

Cash Flow / Share (Quarterly)$0.93

Price vs S&P 500 (YTD)-7.35%

Gross Margin (TTM)74.84%

Net Profit Margin (TTM)7.35%

EPS (TTM)$0.36

10-Day Avg Trading Volume0.55M

EPS Excl Extra (TTM)$0.36

Revenue Growth (5Y)17.34%

EPS (Annual)$0.32

ROI (Annual)4.63%

Gross Margin (Annual)74.42%

Net Profit Margin (5Y Avg)-1.24%

Cash / Share (Quarterly)$2.85

P/E Basic Excl Extra (TTM)82.66x

Revenue Growth QoQ (YoY)30.09%

EPS Growth (5Y)38.88%

P/E Normalized (Annual)107.40x

ROA (Last FY)3.39%

Revenue Growth TTM (YoY)22.45%

EBITD / Share (TTM)$0.53

ROE (5Y Avg)-1.26%

Operating Margin (TTM)5.40%

Cash Flow / Share (Annual)$0.49

P/B Ratio4.98x

P/B Ratio (Quarterly)4.60x

Net Income / Employee (Annual)$41,500

EV / Revenue (TTM)5.70x

Net Interest Coverage (TTM)-1.38x

ROA (TTM)4.61%

EPS Growth QoQ (YoY)23.36%

EV / EBITDA (TTM)59.70x

EPS Incl Extra (Annual)$0.32

Current Ratio (Annual)5.03x

Quick Ratio (Quarterly)4.79x

3-Month Avg Trading Volume0.61M

52-Week Price Return-16.36%

EV / Free Cash Flow (Annual)67.30x

P/E Incl Extra (TTM)82.66x

Revenue / Employee (TTM)$733,900

Tangible BV / Share (Quarterly)$6.88

P/S Ratio (Annual)6.42x

Asset Turnover (Annual)0.57x

52-Week High$45.97

Operating Margin (5Y Avg)-2.57%

EPS Excl Extra (Annual)$0.32

CapEx CAGR (5Y)59.51%

Tangible BV CAGR (5Y)78.61%

26-Week Price Return-9.81%

Quick Ratio (Annual)4.68x

13-Week Price Return6.76%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)5.18x

Enterprise Value$1.67B

Revenue / Share Growth (5Y)15.07%

Asset Turnover (TTM)0.63x

Book Value / Share Growth (5Y)19.03%

Revenue / Employee (Annual)$694,100

Inventory Turnover (Annual)4.05x

Pretax Margin (Annual)6.29%

Cash / Share (Annual)$2.72

3-Month Return Std Dev45.88%

Gross Margin (5Y Avg)70.05%

Net Income / Employee (TTM)$53,900

EBITDA CAGR (5Y)36.42%

EBITDA Interim CAGR (5Y)14.38%

ROE (Last FY)4.66%

Net Interest Coverage (Annual)-2.43x

EPS Basic Excl Extra (Annual)$0.32

P/FCF (TTM)37.36x

Receivables Turnover (TTM)4.66x

EV / Free Cash Flow (TTM)35.07x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$0.36

Receivables Turnover (Annual)3.78x

ROI (TTM)6.39%

P/S Ratio (TTM)6.07x

Pretax Margin (5Y Avg)-1.02%

Revenue / Share (Annual)$5.30

Tangible BV / Share (Annual)$6.89

Forward P/E53.59x

Free OCF CAGR (5Y)10.62%

Price vs S&P 500 (52W)-40.73%

P/E Ratio (TTM)82.66x

EPS Growth TTM (YoY)100.99%

Year-to-Date Return0.81%

5-Day Price Return10.60%

EPS Normalized (Annual)$0.32

ROA (5Y Avg)-0.86%

Net Profit Margin (Annual)5.98%

Month-to-Date Return8.91%

Cash Flow / Share (TTM)$-0.12

EBITD / Share (Annual)$0.43

Operating Margin (Annual)4.00%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)28.76x

ROI (5Y Avg)-1.26%

P/E Excl Extra (TTM)82.66x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$0.36

P/TBV (Quarterly)4.67x

P/B Ratio (Annual)5.14x

Inventory Turnover (TTM)4.15x

Pretax Margin (TTM)7.64%

Book Value / Share (Annual)$7.01

Price vs S&P 500 (13W)-1.49%

Net Margin Growth (5Y)20.74%

Beta1.11x

P/FCF (Annual)71.69x

Revenue / Share (TTM)$5.75

ROE (TTM)6.41%

52-Week Low$28.95

vGradeD

gGradeB

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.12est. -0.16

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.21

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
VCELVericel Corporation	D	B	C	$36.30
AMGNAmgen Inc	C	C	C	$349.58
GILDGilead Sciences Inc	C	B	C	$129.16
ARGXargenx SE American Depositary Shares	D	A	B	$891.32
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$149.23
BIIBBiogen Inc. Common Stock	B	D	B	$195.34
BNTXBioNTech SE American Depositary Share	C	C	D	$88.08
MRNAModerna, Inc. Common Stock	C	B	B	$47.44
NBIXNeurocrine Biosciences Inc	C	B	B	$163.88
EXELExelixis Inc	C	B	B	$52.70
KRYSKrystal Biotech, Inc. Common Stock	D	B	A	$301.00

About

Vericel is a biopharmaceutical company specializing in advanced cell therapies for sports medicine and severe burn care in the U.S. market. Its portfolio includes MACI (autologous cultured chondrocytes) for cartilage repair, Epicel (cultured epidermal autografts) for burn treatment, and NexoBrid. The company handles the full value chain from research and development through manufacturing and distribution.